Regression of left ventricular hypertrophy by acebutolol and nifedipine

Cardiovasc Drugs Ther. 1989 Jun:3 Suppl 1:313-7. doi: 10.1007/BF00148476.

Abstract

Fourteen patients with previously untreated essential hypertension and left ventricular hypertrophy were treated with a fixed-dose combination of acebutolol 200 mg and nifedipine 20 mg once daily for a followup of 25.6 +/- 1.8 months. Echocardiography showed a significant decrease after a mean period of 6.6 months in interventricular septal thickness (14.8%, p less than 0.001), posterior wall thickness (14.8%, p less than 0.001), and left ventricular mass index (21.3%). After 25.6 months, the reductions were 29% (p less than 0.001), 28.1% (p less than 0.001), and 38.7% (p less than 0.001), respectively. Left wall thickness was significantly reduced, but left ventricular end-systolic and end-diastolic dimensions and fractional shortening remained unchanged. Treatment reduced resting blood pressure from 161/102 mmHg to 132/87 mmHg (p less than 0.001) and reduced exercise blood pressure at 100 W from 208/113 mmHg to 170/94 mmHg (p less than 0.001). Thus, nifedipine in combination with acebutolol produces significant blood-pressure reduction accompanied by regression of left ventricular hypertrophy without noticeable changes in left ventricular function.

MeSH terms

  • Acebutolol / therapeutic use*
  • Blood Pressure / drug effects
  • Cardiomegaly / drug therapy*
  • Cardiomegaly / etiology
  • Drug Combinations
  • Echocardiography / drug effects
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy*
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Nifedipine / therapeutic use*

Substances

  • Drug Combinations
  • Acebutolol
  • Nifedipine